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Abstract: Rho-kinase (ROCK) is a serine/threonine kinase and one of the major downstream 
effectors of the small GTPase Rho. The Rho-ROCK pathway is involved in many aspects of 
neuronal functions including neurite outgrowth and retraction. The Rho-ROCK pathway becomes 
an attractive target for the development of drugs for treating central nervous system (CNS) dis-
orders, since it has been recently revealed that this pathway is closely related to the pathogenesis 
of several CNS disorders such as spinal cord injuries, stroke, and Alzheimer’s disease (AD). In 
the adult CNS, injured axons regenerate poorly due to the presence of myelin-associated axonal 
growth inhibitors such as myelin-associated glycoprotein (MAG), Nogo, oligodendrocyte-
myelin glycoprotein (OMgp), and the recently identiﬁ  ed repulsive guidance molecule (RGM). 
The effects of these inhibitors are reversed by blockade of the Rho-ROCK pathway in vitro, 
and the inhibition of this pathway promotes axonal regeneration and functional recovery in the 
injured CNS in vivo. In addition, the therapeutic effects of the Rho-ROCK inhibitors have been 
demonstrated in animal models of stroke. In this review, we summarize the involvement of the 
Rho-ROCK pathway in CNS disorders such as spinal cord injuries, stroke, and AD and also 
discuss the potential of Rho-ROCK inhibitors in the treatment of human CNS disorders.
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Introduction
The Rho family of small GTPases, including Rho, Rac, and Cdc42, has a central role 
in cellular motility and cytokinesis due to its involvement in the regulation of actin 
cytoskeletal dynamics (Fukata et al 2003; Riento and Ridley 2003; Narumiya and 
Yasuda 2006). As with other small GTPases, Rho functions as a molecular switch 
that controls various intracellular signaling pathways by shuttling between an active 
(GTP-bound) and inactive (GDP-bound) state. The exchange between the GTP- and 
GDP-bound forms is controlled by several regulatory proteins. Guanine nucleotide 
exchange factors (GEFs) enhance the conversion of a GDP-bound form to a GTP-bound 
form, which results in Rho activation. The GTP-bound form of Rho subsequently 
interacts with its speciﬁ  c downstream targets and triggers intracellular signalling 
cascades. On the contrary, GTPase activating proteins (GAPs) stimulate the GTPase 
activity of Rho, which leads to the conversion of an active GTP-bound form to an 
inactive GDP-bound form. Furthermore, guanine nucleotide dissociation inhibitors 
(GDIs) maintain Rho in an inactive GDP-bound form by sequestering it in the cytosol. 
One of the well-characterized downstream effectors of Rho is the Rho-associated, 
coiled-coil-containing protein kinase (ROCK) (Leung et al 1995; Ishizaki et al 1996; 
Matsui et al 1996). ROCK is a serine/threonine protein kinase with a molecular mass 
of 160 kDa. Two isoforms of ROCK exist, ie, ROCKI and ROCKII, and these show 
65% similarity in their amino acid sequences and 92% identity in their kinase domains. 
The kinase domain of both ROCK isoforms is located at the amino terminus, and this 
is followed by a coiled-coil domain containing the Rho-binding site (RBD) and a Therapeutics and Clinical Risk Management 2008:4(3) 606
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pleckstrin-homology domain (PH) with an internal cysteine-
rich domain (CRD) at the carboxyl terminus (Figure 1A) 
(Riento and Ridley 2003; Mueller et al 2005). The carboxyl 
terminal domain forms an autoinhibitory loop that folds back 
onto the catalytic domain and reduces the kinase activity of 
ROCK (Amano et al 1999). It has been suggested that the 
GTP-bound form of Rho activates ROCK by binding to the 
RBD in ROCK and counteracting the inhibitory interaction 
between the catalytic domain and the autoinhibitory region 
(Figure 1B).
With respect to tissue distribution, ROCKI and ROCKII 
transcripts are ubiquitously but differentially expressed 
(Nakagawa et al 1996). ROCKII is preferentially expressed 
in brain and muscle tissues, whereas ROCKI is abundantly 
expressed in nonneuronal tissues such as the liver, stom-
ach, spleen, kidney, and testis. Both transcripts are highly 
expressed in the heart and lung. Although the two ROCK 
isoforms have been reported to have differential tissue dis-
tribution, the functional differences between them are less 
characterized. One such difference has been described in 
the process of membrane blebbing during apoptosis. In this 
case, it was demonstrated that caspase-3-dependent ROCKI 
cleavage removed the inhibitory domain of ROCKI, thereby 
rendering it constitutively active: this induced membrane 
blebbing during the course of apoptosis (Coleman et al 
2001; Sebbagh et al 2001). Interestingly, ROCKII was not 
activated by caspase-3 since it lacked the cleavage site. On 
the contrary, ROCKII, not ROCKI, was speciﬁ  cally truncated 
and activated by a proapoptotic protease granzyme B in a 
caspase-independent manner during the membrane blebbing 
process (Sebbagh et al 2005). Gene deletion of ROCKI or 
ROCKII in mice also demonstrated the functional differences 
between the 2 isoforms (Thumkeo et al 2003; Shimizu et al 
2005). Most ROCKII-deﬁ  cient mice show embryonic lethal-
ity probably due to a defect in the placenta with thrombosis, 
whereas failure of eyelid closure and closure of the ventral 
body wall has been reported in ROCKI-knockout mice. 
However, detailed analysis demonstrated that the latter phe-
notypic defects were also evident in ROCKII-knockout mice, 
suggesting that both isoforms share some aspects of the same 
Figure 1 A schematic drawing of ROCKI and ROCK activation by Rho. (A) ROCKI has the kinase domain at the amino terminus, followed by a coiled-coil domain containing the 
Rho-binding site (RBD), and a pleckstrin-homology domain (PH) with an internal cysteine-rich domain (CRD). ROCKII has a very similar structure. (B) A proposed mechanism 
of ROCK activation by GTP-bound Rho is shown (Amano et al 1999). The carboxyl terminal domain forms an autoinhibitory loop that folds back onto the kinase domain and 
inhibits the kinase activity of ROCK. GTP-bound Rho binds to the RBD region in ROCK and renders the catalytic domain of ROCK to be accessible to its substrates, which 
results in the activation of ROCK.
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biological functions. It is noteworthy that after overcoming 
the perinatal problems, both ROCKI- and ROCKII-deﬁ  cient 
mice develop normally without any obvious anatomical and 
functional abnormalities.
ROCK regulates the activities of many target proteins by 
its kinase activity. Some of these proteins such as the myosin 
light chain (MLC) regulate cell morphology (Brown and 
Bridgman 2004). Phosphorylated MLC induces actomyosin 
contraction by enhancement of myosin ATPase activity, 
which is a key step in cytoskeletal rearrangement (Ikebe and 
Hartshorne 1985; Ikebe et al 1986; Brown and Bridgman 
2004). ROCK also increases MLC phosphorylation via the 
inhibition of MLC phosphatase by phosphorylation. Other 
ROCK substrates include the LIM (Lin11/Isl1/Mec3) kinases 
(Ohashi et al 2000; Sumi et al 2001) and collapsin response 
mediator protein-2 (CRMP-2) (Arimura et al 2000, 2004), 
all of which are involved in the regulation of cytoskeletal 
reorganization.
Since a large number of reports have demonstrated the 
involvement of the Rho-ROCK pathway in the pathogenesis 
of several diseases, the Rho-ROCK pathway is considered 
to be a promising target for drug development in ﬁ  elds such 
as cardiovascular disease, cancer, erectile dysfunction, 
renal disease, and central nervous system (CNS) disorders 
(Cellek 2002; Shimokawa 2002; Lepley et al 2005; Mueller 
et al 2005; Nishikimi and Matsuoka 2006; Kubo et al 2007; 
Shimokawa and Rashid 2007). In this review, we summarize 
recent progress that has been made in understanding the 
involvement of the Rho-ROCK pathway in CNS disorders 
and discuss the potentials of Rho-ROCK inhibitors as phar-
macotherapeutic drugs for treating CNS disorders.
Spinal cord injury
It is well known that in comparison to the axons of the 
peripheral nervous system (PNS), those of the adult mamma-
lian CNS, including the spinal cord, regenerate poorly after 
injury. The lack of appropriate axonal regeneration in the 
CNS frequently results in permanent neuronal deﬁ  cits such 
as paralysis following traumatic damage such as spinal cord 
injury. The pathology of CNS injuries, particularly spinal 
cord injuries, has been understood at a molecular level. It has 
been demonstrated that the lack of regeneration of injured 
CNS axons was mainly due to the CNS environment itself 
rather than due to any intrinsic disability of CNS nerve ﬁ  bers 
(Richardson et al 1980; David and Aguayo 1981). At present, 
3 axon outgrowth inhibitors in CNS myelin—Nogo, myelin-
associated glycoprotein (MAG), and oligodendrocyte-myelin 
glycoprotein (OMgp)—have been well documented (Mueller 
et al 2005; Yamashita et al 2005; Kubo et al 2007). Nogo has 
3 different isoforms, ie, NogoA, NogoB, and NogoC. NogoA 
is mainly expressed by CNS oligodendrocytes, whereas 
NogoB and NogoC are widely distributed outside the CNS. 
Nogo-66a, which is one of the inhibitory domains in the Nogo 
protein, is located in the C-terminal region that is common 
to the 3 isoforms (Fournier et al 2001; Oertle et al 2003). 
MAG, which is the ﬁ  rst myelin-associated axon outgrowth 
inhibitor to be identiﬁ  ed, is a transmembrane protein of the 
immunoglobulin superfamily and is distributed in both PNS 
and CNS myelin (McKerracher et al 1994; Mukhopadhyay 
et al 1994; Li et al 1996). OMgp, a glycosylphosphatidylino-
sitol (GPI)-anchored 110-kDa glycoprotein, is located in 
oligodendrocytes and has an inhibitory effect on neurite 
outgrowth that is as potent as that of Nogo-66a (Kottis 2002; 
Wang 2002b). Interestingly, these 3 structurally distinct 
myelin-associated inhibitors bind to the same receptor, ie, 
NgR, which is a GPI-anchored protein and is expressed 
in CNS neurons as well as in their axons (Josephson et al 
2002; Wang 2002c). Since the GPI-linked NgR lacks an 
intracellular domain, it was assumed that a coreceptor that 
activates the intracellular signaling cascade was present. The 
low-afﬁ  nity neurotrophin receptor p75NTR has been identiﬁ  ed 
as an NgR coreceptor. Initially, we reported that p75NTR is 
required for neurite outgrowth inhibition by MAG by using 
postnatal dorsal root ganglion (DRG) neurons from mutant 
mice with a mutation in the p75NTR gene (Yamashita et al 
2002). Subsequently, it was found that p75NTR and NgR 
form a receptor complex for MAG and the other 2 inhibi-
tors, ie, Nogo and OMgp, suggesting that p75NTR induces the 
intracellular inhibitory signals of all these myelin-associated 
proteins in association with NgR (Figure 2) (Wang et al 
2002a; Wong et al 2002). Thereafter, Lingo-1 was identiﬁ  ed 
as an additional component of the receptor complex with 
NgR and p75NTR (Mi et al 2004). However, whether NgR is 
required for neurite outgrowth inhibition by the inhibitors is 
still debatable (Zheng et al 2005; Chivatakarn et al 2007). 
It has been recently demonstrated that NgR1 only mediates 
growth cone collapse, not neurite outgrowth inhibition, 
triggered by these inhibitors (Chivatakarn et al 2007). In 
contrast to NgR, p75NTR is involved in both growth cone 
collapse and neurite outgrowth inhibition induced by the 
inhibitors, suggesting that an unidentiﬁ  ed receptor complex 
containing p75NTR mediates neurite outgrowth inhibition trig-
gered by the inhibitors (Figure 2) (Wang et al 2002a; Wong 
et al 2002; Yamashita et al 2002; Chivatakarn et al 2007). 
Further studies revealed that TROY (also known as TAJ), a 
member of the tumor necrosis factor (TNF) receptor family, Therapeutics and Clinical Risk Management 2008:4(3) 608
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formed a functional receptor complex with NgR and Lingo-1, 
which mediates the inhibitory activity of myelin-associated 
inhibitors (Park et al 2005; Shao et al 2005). These suggest 
that several types of receptor complexes convey the inhibitory 
actions of myelin-associated inhibitors (Figure 2).
Nogo, MAG, and OMgp clearly inhibit neurite outgrowth 
in vitro; however, their involvement in axonal outgrowth 
inhibition following in vivo CNS injury remains debatable. 
Although blockade of the Nogo-NgR pathway by a 
neutralizing antibody (Schnell and Schwab 1990; Bregman 
et al 1995; Brosamle et al 2000; Merkler et al 2001) or 
its antagonistic peptide NEP1-40 (GrandPre et al 2002; 
Li and Strittmatter 2003) promoted axonal outgrowth and 
functional recovery in rats with spinal cord injury, Nogo- or 
NgR-deﬁ  cient mice exhibited conﬂ  icting results (Kim et al 
2003; Simonen et al 2003; Zheng et al 2003, 2005; Kim et al 
2004; Dimou et al 2006). In addition, MAG-knockout mice 
or mice with the mutant p75NTR gene did not exhibit better 
functional recovery and axonal regeneration after spinal cord 
injury (Bartsch et al 1995; Li et al 1996; Song et al 2004).
Recently, we discovered that the repulsive guidance 
molecule (RGMa) acts as another myelin-associated neurite 
outgrowth inhibitor that induces inhibitory signals inde-
pendent of the NgR pathway (Figure 2) (Hata et al 2006; 
Yamashita et al 2007b). RGMa is a 33-kDa GPI-anchored 
protein, and neogenin has been found to be a functional 
receptor for RGM (Rajagopalan et al 2004; Yamashita et al 
2007b). We found that RGMa signiﬁ  cantly inhibits neurite 
outgrowth in cultured neurons (Hata et al 2006; Kubo et al 
in press). Interestingly, a neutralizing anti-RGMa antibody 
signiﬁ  cantly enhances axonal outgrowth and functional 
recovery in rats with spinal cord injury (Hata et al 2006), 
suggesting that RGMa causes poor axonal regeneration and 
functional recovery after spinal cord injury in addition to 
other myelin-associated inhibitors.
Since there are several types of myelin-associated neurite 
outgrowth inhibitors, a strategy to block a common intracel-
lular effector molecule(s), if any, would be more effective. 
Recent studies have revealed that these myelin-associated 
inhibitors trigger the axonal growth-inhibitory signals via 
Figure 2 Intracellular signal cascades of myelin-associated neurite outgrowth inhibitors. Myelin-associated neurite outgrowth inhibitors such as Nogo, MAG, and OMgp bind to 
the same receptor, namely, NgR. A receptor complex containing p75NTR mediates the inhibitory signals such as growth cone collapse and neurite outgrowth inhibition via the 
activation of Rho and ROCK. NgR is reported to be only involved in the pathway resulting in growth cone collapse (I), but not in the pathway resulting in neurite outgrowth 
inhibition (II), which suggests that an unknown receptor for the neurite outgrowth inhibitors mediates the latter pathway (Chivatakarn et al 2007). In some neurons, TROY 
might be involved in this cascade instead of p75NTR. RGMa binds to a different receptor, namely, neogenin and also activates the Rho-ROCK pathway. Other neurite outgrowth 
inhibitors such as chondroitin sulfate proteoglycans (CSPGs) and members of the semaphorin and ephrin families are also reported to activate the Rho-ROCK pathway for 
their inhibitory functions (not shown).
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the Rho-ROCK pathway (Figure 2) (Mueller et al 2005; 
Yamashita et al 2005; Kubo et al 2007). Botulinum toxin C3, 
which speciﬁ  cally inactivates Rho by enzymatic adenosine 
diphosphate (ADP)-ribosylation of the active site in Rho 
blocks neurite outgrowth inhibition by myelin and MAG 
(Lehmann et al 1999). Speciﬁ  c ROCK blockers such as 
Y-27632 counteract the inhibitory effects of these myelin-
associated proteins on neurons (Dergham et al 2002; Fournier 
et al 2003; Hata et al 2006; Kubo et al in press). Rho activation 
by outgrowth inhibitors such as MAG and Nogo is mediated 
through p75NTR, which enhances the dissociation of the Rho-
guanine nucleotide dissociation inhibitor (Rho-GDI) from 
RhoA after stimulation by the neurite outgrowth inhibitors 
(Yamashita and Tohyama 2003). Thereafter, RhoA activation 
is promoted by the Rho-guanine nucleotide exchange factor 
(Rho-GEF), which converts RhoA from an inactive GDP form 
to an active GTP form. In addition, a recent report demon-
strated that intracellular proteolysis of p75NTR is essential for 
both Rho activation and neurite outgrowth inhibition induced 
by MAG (Domeniconi et al 2005). Regarding the downstream 
effectors of the Rho-ROCK pathway, we recently reported that 
inactivation of CRMP-2 by ROCK-induced phosphorylation 
results in neurite outgrowth inhibition downstream of MAG 
(Mimura et al 2006). It has also been demonstrated that RhoA 
mediates the actions of myelin-associated neurite outgrowth 
inhibitors through direct binding to CRMP-4 (Alabed et al 
2007). Furthermore, we found that RGMa inhibits neurite 
outgrowth through the activation of the RhoA-ROCK pathway 
in cultured neurons (Hata et al 2006; Kubo et al in press). In 
this case, the activation of myosin IIA, which is one of the 
downstream effectors of ROCK, is a key step for the exertion 
of the inhibitory effects of RGMa (Kubo et al in press). Most 
of the other documented neurite outgrowth inhibitors such as 
chondroitin sulfate proteoglycans (CSPGs) and members of 
the semaphorin and ephrin families are also reported to use 
the Rho-ROCK pathway for their inhibitory functions (Wahl 
et al 2000; Shamah et al 2001; Swiercz et al 2002; Monnier 
et al 2003; Lingor et al 2007). Therefore, Rho-ROCK is one of 
the most appropriate drug targets for counteracting the effects 
elicited by the different types of neurite outgrowth inhibitors.
In addition to Rho-ROCK, several other proteins have 
been identiﬁ  ed as effectors of neurite outgrowth inhibitors, 
including conventional protein kinase C (PKC) (Hasegawa 
et al 2004; Sivasankaran et al 2004; Conrad et al 2007), 
glycogen synthase kinase (GSK)-3 (Eickholt et al 2002; Ito 
et al 2006), and the epidermal growth factor (EGF) receptor 
(Koprivica et al 2005). At least in vitro, multiple signals 
mediate the effects of the myelin-derived inhibitors.
After spinal cord injury, RhoA activation is detected in 
both the neurons and glial cells around the lesion site (Dubreuil 
et al 2003; Madura et al 2004), suggesting that activated Rho 
is involved in blocking CNS regeneration and providing a 
strategy to promote the regeneration of injured CNS axons by 
reversing this inhibitory pathway in vivo. The in vivo thera-
peutic effects of Rho inactivation were demonstrated following 
optic nerve injury. C3 transferase (C3) and its cell-permeable 
derivatives such as C3-05 and C3-07, which are speciﬁ  c Rho 
inhibitors, promote axonal regeneration after optic nerve injury 
(Lehmann et al 1999; Fischer et al 2004; Bertrand et al 2005). 
Subsequently, local application of C3 to the lesion site showed 
beneﬁ  cial effects on histological and functional recovery in 
spinal cord transection injuries (Dergham et al 2002). ROCK 
inactivation also exerts therapeutic effects on CNS injury. In 
rodent spinal cord injury, fasudil, which is the only clinically 
available ROCK inhibitor, and Y-27632, another ROCK 
inhibitor, enhance axonal regrowth and functional recovery 
(Hara et al 2000; Dergham et al 2002; Fournier et al 2003; 
Sung et al 2003). We also found that the cytoplasmic ROCK 
inhibitory protein p21Cip1/WAF1 promoted the sprouting and 
regeneration of CST ﬁ  bers and functional recovery in rat spinal 
cord hemisection injuries (Tanaka et al 2004). In addition, 
it was reported that Rho-ROCK inactivation exerts neuro-
protective effects after spinal cord and optic nerve injuries 
and decreases tissue damage and cavity formation, which is 
another beneﬁ  cial aspect of Rho-ROCK inhibition (Dubreuil 
et al 2003; Fischer et al 2004; Tanaka et al 2004; Bertrand 
et al 2005). These data in animal models strongly suggest that 
Rho-ROCK inhibitors provide therapeutic beneﬁ  ts in patients 
with spinal cord injury (Mueller et al 2005; McKerracher and 
Higuchi 2006; Kubo et al 2007).
Stroke
Ischemic stroke such as cerebral infarction is one of the 
primary CNS disorders and is associated with high morbid-
ity and mortality. Animal models with permanent middle 
cerebral artery (MCA) occlusion demonstrated that infarction 
in the ischemic core occurs very rapidly after induction of 
ischemia and that ischemic damage expands to the peripheral 
region (ischemic penumbra) with time (Garcia et al 1993). 
Therefore, the main therapeutic target of ischemic stroke is 
the peripheral region. There is evidence to demonstrate that 
Rho-ROCK inhibition by C3; fasudil; hydroxyfasudil, which 
is an active metabolite of fasudil; and Y-27632 protects 
against ischemia-induced brain damage (Laufs et al 2000; 
Toshima et al 2000; Satoh et al 2001; Rikitake et al 2005). It 
has been suggested that the therapeutic effect is at least partly Therapeutics and Clinical Risk Management 2008:4(3) 610
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mediated by the upregulated expression of endothelial NO 
synthase by Rho-ROCK inhibition and the resultant increase 
in cerebral blood ﬂ  ow (Laufs et al 2000; Rikitake et al 2005). 
In addition, fasudil and hydroxyfasudil were reported to have 
a direct neuroprotective effect (Yamashita et al 2007a). It is 
noteworthy that delayed treatment with fasudil also prevents 
ischemia-induced neuronal death in the CA1 region of the 
gerbil hippocampus, suggesting that ROCK inhibition has 
a wide therapeutic time window in the treatment of isch-
emic stroke (Satoh et al 2007). Fasudil is currently the only 
clinically available ROCK inhibitor and was launched in 
Japan in1995 to treat cerebral vasospasm after subarach-
noid hemorrhage (Shibuya et al 1992). Several groups have 
performed clinical trials of fasudil for patients with angina 
(Shimokawa et al 2002; Vicari et al 2005) or acute ischemic 
stroke (Shibuya et al 2005), and fasudil exerted signiﬁ  cant 
therapeutic effects in both diseases. In the clinical trials 
for stroke, enrolled patients (160 patients) received fasudil 
within 48 h of ischemic stroke onset, and 60 mg of fasudil 
was administered via intravenous injection twice daily for 14 
days. Fasudil signiﬁ  cantly improved both the neurological 
functions and clinical outcome of the patients and showed 
no severe side effects (Shibuya et al 2005). These results 
strongly suggest that Rho-ROCK inhibitors are beneﬁ  cial 
and safe treatment options for ischemic stroke patients.
Alzheimer’s disease
Alzheimer’s disease (AD) is one of the most common causes 
of progressive dementia with massive neurodegeneration. The 
histopathological hallmarks of AD are extracellular deposits 
of senile plaques, which are composed of β-amyloid (Aβ) 
peptides, and intracellular neuroﬁ  brillary tangles composed 
of hyperphosphorylated tau proteins. Aβ 1–40 and the more 
amyloidogenic Aβ 1–42 are produced by sequential proteo-
lytic cleavage of the amyloid precursor protein (APP) by 
β- and γ-secretase, whereas α-secretase cleaves APP within 
the Aβ domain and produces no Aβ peptides (Hardy and 
Selkoe 2002; Walsh and Selkoe 2004). Results from studies 
on genetic mutations and neurotoxicity strongly suggest that 
Aβ peptides, particularly soluble oligomers of Aβ peptides, 
play key roles in the pathogenesis of AD (Walsh and Selkoe 
2004; Venkitaramani et al 2007). Epidemiological studies 
demonstrated that the risk of AD development is reduced 
in users of some types of drugs such as nonsteroidal anti-
inﬂ  ammatory drugs (NSAIDs) (McGeer et al 1990, 1996; 
Anthony et al 2000) and statins, which are cholesterol-
lowering HMGCoA reductase inhibitors (Jick et al 2000; 
Wolozin et al 2000; Rockwood et al 2002; Yaffe et al 2002). 
It was reported that some types of NSAIDs selectively reduce 
the production of amyloidogenic Aβ 1–42 both in vitro and 
in vivo, independent of their inhibitory effects on cyclooxy-
genase (COX) activity (Weggen et al 2001, 2003; Eriksen 
et al 2003; Sagi et al 2003; Takahashi et al 2003; Beher et al 
2004; Kukar et al 2005). Among these compounds, R-ﬂ  ur-
biprofen, which is an enantiomer of the classical racemic 
NSAID ﬂ  urbiprofen, has reduced COX inhibitory activity and 
thus less toxicity (Morihara et al 2002; Eriksen et al 2003). 
R-Flurbiprofen lowered the levels of Aβ 1–42 and improved 
learning and memory deﬁ  cits in a transgenic animal model 
of AD (Eriksen et al 2003; Kukar et al 2007). It also exerted 
beneﬁ  cial effects in AD patients in a phase II clinical trial 
(Black et al 2006; Galasko et al 2007; Geerts 2007). It has 
been suggested that the inhibitory effects of NSAIDs on Aβ 
1–42 production are related to inhibition of the Rho-ROCK 
pathway both in cell cultures and in a transgenic mouse model 
of AD (Zhou et al 2003). However, many other groups have 
suggested that the decrease in Aβ 1–42 production by these 
NSAIDs is due to their direct inhibitory effects on γ-secretase 
rather than due to the inhibition of the Rho-ROCK pathway 
(Eriksen et al 2003; Takahashi et al 2003; Weggen et al 
2003; Beher et al 2004; Kukar et al 2005; Leuchtenberger 
et al 2006). Statins are also reported to reduce Aβ produc-
tion in cell cultures and a transgenic mouse model of AD 
(Fassbender et al 2001; Petanceska et al 2002). The inhibition 
of Aβ production by statins is mediated by both the cholesterol 
lowering-dependent and -independent mechanisms (Cole and 
Vassar 2006). Although the precise molecular mechanisms 
remain to be determined, the reduction of Aβ by statins is at 
least partly attributed to the enhancement of α-secretase activ-
ity (Kojro et al 2001; Parvathy et al 2004). Independent of the 
depletion of cellular cholesterol levels, statins inhibit small 
GTPases including Rho by lowering protein isoprenylation 
via the reduction of mevalonate synthesis (Cole and Vassar 
2006). It has been suggested that the inhibition of Rho-ROCK 
by statins results in the activation of α-secretase cleavage 
(Pedrini et al 2005) or the enhancement of APP lysosomal 
degradation (Ostrowski et al 2007), both of which lead to 
the inhibition of Aβ production. In addition, it was recently 
reported that Aβ inhibits neurite outgrowth through the activa-
tion of the Rho-ROCK pathway in SH-SY5Y neuroblastoma 
cells (Petratos et al 2008). It was suggested that the inhibitory 
effect of Aβ is at least partly mediated by the induction of an 
alternatively spliced form of CRMP-2, ie, CRMP-2A, and the 
upregulated phosphorylation of CRMP-2 by ROCK. These 
data suggest that the Rho-ROCK pathway is involved not only 
in Aβ production but also in Aβ-induced neurite outgrowth Therapeutics and Clinical Risk Management 2008:4(3) 611
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inhibition, suggesting that Rho-ROCK blockers would be 
beneﬁ  cial in the treatment of AD patients.
Development of Rho-ROCK 
inhibitors
In the case of the Rho inhibitor, the cell-permeable C3 analog 
BA-210 was developed, and this molecule is currently in 
phase I/IIa clinical trials mainly to test its safety and toler-
ability in patients with acute thoracic or cervical spinal cord 
injuries without motor or sensory function (McKerracher 
and Higuchi 2006).
With regard to ROCK inhibitors, several types have 
been reported. Isoquinoline derivatives are typical ROCK 
inhibitors, and fasudil is one example (Figure 3) (Uehata et al 
1997; Shimokawa 2002; Sasaki et al 2002). Fasudil blocks 
ROCK by competitive association with the ATP binding site 
of the kinase with a Ki value of 0.4 µM (Nagumo et al 2000; 
Jacobs et al 2006; Yamaguchi et al 2006a). Both ROCKI and 
ROCKII are inhibited by fasudil with IC50 values of 0.26 µM 
and 0.32 µM, respectively (Shibuya et al 2005). Regarding 
the speciﬁ  city, cAMP-dependent protein kinase (PKA) and 
protein kinase C are also inhibited by fasudil with Ki values of 
1.0 µM and 9.3 µM, respectively (Uehata et al 1997; Sasaki 
et al 2002). Hydroxyfasudil, a major active metabolite of 
fasudil in vivo, is slightly more effective than the original 
compound (Figure 3) (Rikitake et al 2005; Shibuya et al 
2005). Dimethylfasudil (H-1152P) is an optimized derivative 
of fasudil, and it demonstrates higher potency and selectiv-
ity with Ki values of 1.6 nM for ROCK, 630 nM for PKA, 
and 9.27 µM for PKC (Sasaki et al 2002). More selective 
ROCK inhibitors in this category have also been developed 
by improvement of the fasudil and dimethylfasudil molecules 
(Tamura et al 2005). Y-27632, another type of ROCK inhibi-
tor, is in the category of 4-aminopyridine derivatives (Uehata 
et al 1997). Y-27632 inhibits both ROCKI and ROCKII 
by competitively binding to the ATP binding pocket with 
Ki values of 0.22 µM and 0.3 µM, respectively (Ishizaki et al 
2000; Jacobs et al 2006; Yamaguchi et al 2006b). With regard 
to its speciﬁ  city, Y-27632 also inhibits citron kinase, PKN, 
PKC, and PKA with Ki values of 5.3 µM, 3.1 µM, 73 µM, and 
25 µM, respectively (Ishizaki et al 2000). Optimization of this 
series produces a more potent ROCK inhibitor, ie, Y-39983, 
which exerts therapeutic effects on the axonal regeneration 
of crushed optic nerves (Sagawa et al 2007) and reduction of 
hydroxyfasudil fasudil
Y-27632 Y-39983
Dimethylfasudil
(H-1152P)
.2HCl
Figure 3 The chemical structures of ROCK inhibitors.   Two typical ROCK inhibitors, ie, fasudil and Y-27632, and their derivatives are shown. Isoquinoline derivatives, including 
fasudil, hydroxyfasudil, and dimethylfasudil, are represented on the upper side. 4-Aminopyridine derivatives such as Y-27632 and Y-39983 are shown on the lower side.Therapeutics and Clinical Risk Management 2008:4(3) 612
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intraocular pressure, which is beneﬁ  cial in the treatment of 
glaucoma (Nakajima et al 2005; Tokushige et al 2007). Other 
types of ROCK inhibitors have also been described (Mueller 
et al 2005; Kubo et al 2007; Shimokawa and Rashid 2007).
Safety issues
Fasudil, the only clinically available ROCK inhibitor, can be 
used to predict the expected side effects of ROCK inhibitors in 
humans. ROCK inhibition by fasudil in patients with cerebral 
vasospasm does not cause any severe side effects (Shibuya 
et al 1992). Additionally, in clinical trials of fasudil, in which 
patients with stable effort angina or acute ischemic stroke were 
treated, fasudil was well tolerated with no severe side effects, 
including none on the blood pressure and heart rate (Shimo-
kawa et al 2002; Shibuya et al 2005; Vicari et al 2005).
However, ROCKI- or ROCKII-knockout mice exhibited 
developmental abnormalities (Thumkeo et al 2003; Shimizu 
et al 2005), and the administration of Y-27632 to mouse 
embryos resulted in severe prenatal defects (Wei et al 2001). 
These data strongly indicate that ROCK has critical functions 
during the developmental stage. Interestingly, it was recently 
reported that ROCK inhibition by the intracerebroventricular 
administration of Y-27632 increases anxiety-related behavior 
in mouse emotional behavior tests (Saitoh et al 2006). In 
addition, long-term topical administration of high doses of 
Y-39983 to the eyes results in sporadic punctate subconjunc-
tival hemorrhage in rabbit and monkey eyes (Tokushige et al 
2007). Therefore, further evaluation is required to assess the 
safety of ROCK inhibitors.
Concluding remarks
In this review, we summarize the therapeutic effects of Rho-
ROCK inhibitors in animal models of CNS disorders such as 
spinal cord injuries, stroke, and AD. Further, in stroke patients, 
ROCK inhibition by fasudil led to therapeutic effects without 
severe side effects. These data strongly suggest that Rho-ROCK 
inhibition is a promising strategy to overcome CNS disorders 
such as spinal cord injuries, stroke, and AD in humans.
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